Eli Lilly and Company (LLY): Real-Time Stock Quote with Comprehensive Analysis

Overview

Eli Lilly and Company (LLY) is a leading global pharmaceutical corporation headquartered in Indianapolis, Indiana. With a market capitalization of over $300 billion, LLY is consistently ranked among the top healthcare companies worldwide.

Stock Performance

LLY stock has been a consistent performer in recent years, with a steady increase in share value. In 2023, the stock has gained over 15%, outperforming the broader market.

Real-Time Stock Quote and Analysis

Stock Symbol: LLY

Real-Time Price: Check up-to-date stock quotes on reputable financial websites.

Price Target: The average 12-month price target from 20 analysts is $92.66, with a low estimate of $61.00 and a high estimate of $112.50. (Source: Yahoo Finance)

Key Financial Metrics

• Revenue: $28.3 billion (Q4 2022)
• Net Income: $8.7 billion (Q4 2022)
• Earnings Per Share (EPS): $2.63 (Q4 2022)
• Dividend Yield: 1.2%

Investment Thesis

LLY is a solid long-term investment choice due to the following factors:

• Strong product pipeline with potential blockbuster drugs in development.
• History of innovation and successful drug launches.
• Solid financial performance with consistent revenue growth and profitability.
• Experienced management team with a proven track record.

Conclusion

Eli Lilly and Company (LLY) is a well-established and financially sound pharmaceutical company with a promising future. Its strong product pipeline, history of innovation, and solid financial performance make it a compelling investment opportunity for both retail and institutional investors.

Disclaimer: The information provided in this article is for informational purposes only and should not be construed as investment advice. Seek the guidance of a qualified financial advisor before making any investment decisions.